Ab Studio designed antibodies are at clinical stages! GB261, an Fc-Function Enabled and CD3 Affinity De-Tuned CD20/CD3 Bispecific Antibody designed by Ab Studio shows promising new results published in ASH's annual meeting. Click here for more information.
|
Using our proven technology of computer-design and on-bench validation, SEND US YOUR PROTEIN SEQUENCE and we will provide a drug candidate OFFERING IMPROVED BALANCE OF SAFETY, EFFICACY, AND MANUFACTURABILITY.
Partnerships
Multispecific Antibody Discovery Platform - Bring us your targets, we’ll handle the specifics
Ab Studio’s robust computer-aided platforms, on-bench validation, and expertise in antibody design and optimization has led to promising clinical programs from both out-licensed assets and CRO projects.
We welcome the opportunity for collaboration! Please contact us to start a discussion.
